UHS - Here's Why You Should Retain Glaukos Stock for Now | Benzinga
Glaukos Corporation (NYSE: GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry's 5.4% growth. The S&P 500 Index has also increased 15% in the same time frame.
Glaukos, with a market capitalization of $5.91 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 1.3% for 2024, followed by 43.1% growth in 2025, and expects to maintain its strong performance in terms of revenues as well.
The company has a trailing four-quarter average negative earnings surprise of 4.74%.
Image Source: Zacks Investment Research
Key Catalysts
In 2023, Glaukos witnessed sales returning to growth after experiencing a downturn in 2022. This positive shift can be attributed to a more favorable macroeconomic climate and the introduction of a series of new products in recent quarters. The first-quarter results also reflected the strength. The company anticipates sustained robust demand in its international Glaucoma and Corneal Health product lines to support its top-line growth in the rest of 2024.
The commercial launch of the iStent infinite in 2023 has provided a significant lift to the U.S. glaucoma franchise, positioning it as a key growth catalyst in the forthcoming quarters. The company's optimistic revenue projections for 2024 indicate a positive trajectory.
Meanwhile, the new local coverage determinations, proposed in June 2023, are likely to remove certain ophthalmic goniotomy and ...